ARTICLE | Finance
Quick turn
How Atlas repackaged Saniona assets and set up an exit path within a year
March 24, 2014 7:00 AM UTC
In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase I study of an undisclosed program. At that point, new investor Biogen Idec Inc. (NASDAQ:BIIB) can exercise an option to acquire the ataxia company.
In addition to participating in last week's round, Biogen Idec will provide non-dilutive R&D and other funding to Ataxion...